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Fistula First: A Timely Approach for Successful Dialysis
Access?
Kathleen O. Maxfield2, Erika R. Ketteler1, John D. Cor-
son1, James M. Goff1. 1Surgical Service (112), Raymond
G. Murphy VA Medical Center, Albuquerque, NM; 2Uni-
versity of New Mexico School of Medicine, Department of
Surgery, Albuquerque, NM
Objectives: National Kidney Foundation Disease Out-
comes and Quality Initiative (KDOQI) recommends arte-
riovenous fistula (AVF) as the first choice for hemodialysis
access. However, AVF creation does not predict access
success. Primary objectives of the study are to determine
the time from AVF placement to first use, intervention,
abandonment, or failure.
Methods: Retrospective review from July 1, 1998 to
June 30, 2008, identified 483 patients who underwent
dialysis access procedures and included 240 patients who
received an initial AVF. Study endpoints included time
from placement to first use, intervention, abandonment, or
failure. Patient demographics, clinical characteristics, and
comorbidities were compared by endpoints. Statistical
analysis included 2 and Kaplan Meier analysis and Cox
proportional hazards modeling.
Results: One hundred thirty seven of 240 AVF
(57.1%) were used for hemodialysis; 76 (55.5%) matured
without intervention; 61 (44.5%) required intervention.
Mean time to first use was 29.2 weeks and for those
requiring intervention 37.0 weeks. Of the 103 remaining
patients, 58 AVF were abandoned or failed, 26 AVF were
patent but never accessed, and the remaining patients
died or were lost to follow-up. Mean time to abandon-
ment was 44.0 weeks and to failure 19.5 weeks. By
multivariate analysis, diabetes was the only patient char-
acteristic significantly associated with abandonment or
failure.
Conclusions: Despite KDOQI recommendations,
time to first AVF use is long; interventions are frequently
required; and abandonment, failure, and non-use are com-
mon. These findings call into question our “fistula first”
approach to hemodialysis access and should cause us to
reconsider this approach when timely access is required.
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Creating Functional Autogenous Vascular Access in
Older Patients
William C. Jennings, Lesley Landis, Kevin Taubman. Sur-
gery, University of Oklahoma College of Medicine, Tulsa,
Tulsa, OK
Objectives: Arteriovenous fistulas (AVFs) are the pre-
ferred choice for hemodialysis vascular access (VA); however,
there is debate over the utility of AVFs in older patients,
particularly concerning access maturation and functionality.
We reviewed our VA experience in patients 65 years of age.
Methods: We analyzed consecutive VA patients  65
years old with access operations between March 2003 and
November 2009. All patients had ultrasound vessel map-
ping. In addition to overall outcomes review, the data were
stratified into three 10-year increments for further analysis.
Patency rates refer to functional VA.
Results: 422 consecutive VA patients were included in
this study. Ages were 65-94 years (mean  73). 210
(49.7%) were female, 148 (35.1%) patients were diabetic
and 93 (22.0%) were obese. 124 (29.4%) patients had
previous access operations. AVFs constructed were radio-
cephalic in 30 (7.1%) patients, mid-arm direct AVFs in 278
(65.8%) individuals, and 114 (27.1%) transposition AVFs.
No grafts were used for VA in any patient during the study
period. Time to VA use was 0.5- 6 months (mean  1.5
mos). Primary, primary assisted, and cumulative patency
were 55.6%, 93.6%, and 96.6% at 12 months and 40.7%,
89.6%, and 93.6% at 24 months, respectively. Follow-up was
1.5-77 months (mean  16.8 mos). Subgroup age stratifica-
tion [65-74 (n240), 75-84 (n154), 85-94 (n28) years]
found no difference in functional access outcomes. 149 patients
died during the study period, 1.3-61months (mean 19mos)
after access creation.Nodeathswere related to access operations.
Conclusions: AVFs are feasible and offer functional
and timely VA in older patients. There was no difference in
functional access outcomes with subgroup age stratifica-
tion. Overall cumulative patency was 96.6% at 12 months
and 93.6% at 24 months.
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Objectives: PVI is the preferred initial revasculariza-
tion strategy at many centers in patients with critical limb
ischemia (CLI). Using a multicenter, regional database we
sought to determine if previous failed ipsilateral, infraingui-
nal PVI (iiPVI) portends worsened outcomes after subse-
quent lower extremity bypass (LEB) in patients with CLI.
Methods: This is a retrospective cohort analysis of the
Vascular Study Group of New England (VS GNE) database of
infrainguinal lower extremity bypass for CLI (2003-2008).
Study endpoints were major amputation, graft occlusion and
mortality rates at one year, and in-hospital major adverse events
(MAE). Outcomes were determined using Kaplan-Meier analy-
sis and Cox Proportional-Hazard multivariate regression.
Results: Of 1, 153 patients who underwent LEB for
CLI, 71 (6.2%) had a prior failed iiPVI. One year mortality
and in-hospital MAE did not differ between the groups.
Patients undergoing prior iiPVI had significantly higher
rates of graft occlusion and amputation at one year (Table).
Multivariate predictors of 1-yr LEB occlusion were prior
iiPVI (HR 1.8; CI 1.1-2.9), arm vein conduit (HR 1.8; CI
1.1-2.6), and tibial outflow (HR 2.0; CI 1.4-2.9). Multi-
variate predictors of 1-yr major amputation were iiPVI (HR
2.0; CI 1.0-3.7), dialysis (HR 4.2; 2.6-6.6), prior ipsilateral
bypass (HR 1.7; CI 1.1-2.8), tibial outflow (HR 1.9; CI
1.3-2.9), and tissue loss (HR 1.7; CI 1.1-2.7).
Conclusions: Failed iiPVI is an important predictor of
both graft occlusion and major amputation after LEB in CLI
patients.
No
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log
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Bypass
log
rank
Occlusion (1-yr) 16% 31% 0.01 16% 24% 0.08
Amputation (1-yr) 14% 23% 0.08 14% 21% 0.03
Death (1-yr) 10% 13% 0.97 10% 10% 0.95
MAE (in-hospital) 29% 32% 0.5 29% 29% 0.91
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Sustained 5 Years Performance Analysis of Sequential Com-
pression Biomechanical Device (SCBD) in Critical Limb
Ischaemia (CLI) Patients with Un-reconstructable Periph-
eral Vascular Disease (PVD) vs Primary Amputation in a
Tertiary Referral Vascular Centre With Quality of Time
Without the Symptoms or Toxicity of the Disease
(QTWiST)
Sherif Sultan, Nader Hamada, Wael Tawfick, Anne Fahy,
Niamh Hynes. Vascular & Endovascular Surgery, Western
Vascular Institute, Galway, IrelandObjectives: Our aim was assess the clinical efficacy and
economic viability of a SCBD programme for CLI. Primary
endpoints were sustained clinical improvement and ampu-
tation free survival. Secondary endpoints were Q-TWiST
and cost per QALY.
Methods: From 2004 to 2009, we assessed 4538 pa-
tients with PVD. Of which 707 had CLI and 518 had
intervention, while 189 were not candidates for any inter-
vention. Only 170 patients had joined the SCBD pro-
gramme for three months at three hours bi-daily. We
matched controlled 75 primary amputations. All patients
were Rutherford category 4 or more. The median fol-
low-up was 13 months with average of 18.3 months.
Results: Sustained clinical improvement was reported in
68% of patients. Sustained hemodynamic improvement were
notedwith;Mean toe pressure increased from39.9mmHg to
55.42mmHgwith mean difference in Toe Pressure of 15.49
mmHg p 0.0001; andMean Popliteal flow increased from
35.44cm/sec to 55.91cm/sec with Mean Difference in Pop-
liteal Flow of 20.47cm/sec p 0.0001. Thirty-day mortality
was 0.6%.Mean Amputation-free survival rate was 18months
with limb salvage rate at 5years of 94%. Freedom fromMACE
at 5 Years was 62.5%. All cause survival was 68.4%% at 5 years.
Estimatedmedian Inpatient/Total cost of managing a prima-
ry-amputation patient is €29, 815 compared to €3985 for
SCBD.We treated170patientswith artassist at a cost of €681,
965. However, primary amputation for 75 patients had cost
€2, 236, 125 with poor QALY/QTWiST.
Conclusions: SCBD Improves Quality of Life at a
Community Level. This study provides larger scale evi-
dence that SCBD therapy is a cost-effective and clinically
efficacious solution as it has Superior Limb Salvage, Ame-
liorated Amputation Free Survival, Reduced Length of
Hospital Stay and Provided Rapid Relief of Rest Pain
without any Intervention in Patients with Limited Life
Expectancy.
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Bypass in Regards to Healing Rates of Ischemic
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Georgetown University Hospital, Washington, DC
Objectives: Compare wound healing after endovascu-
lar therapy (EV) or lower extremity bypass (LEB) to inves-
tigate equivalence based on tissue results and wound char-
acteristics.
Methods: A retrospective review analyzed 290 patients
undergoing revascularization for an ischemic wound from
January 2004 to December 2008. Inclusion required com-
